

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **August 11, 2026**

**SILICON LABORATORIES INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-29823**  
(Commission File Number)

**74-2793174**  
(IRS Employer  
Identification No.)

**400 West Cesar Chavez, Austin, TX**  
(Address of Principal Executive Offices)

**78701**  
(Zip Code)

Registrant's telephone number, including area code: **(512) 416-8500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class              | Trading Symbol(s) | Name of each exchange<br>on which registered |
|----------------------------------|-------------------|----------------------------------------------|
| Common Stock, \$0.0001 par value | SLAB              | The NASDAQ Stock Market LLC                  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934. ☐

---

---

## Item 2.02. Results of Operations and Financial Condition

On August 11, 2026, Silicon Laboratories Inc. (“Silicon Laboratories”) issued a press release announcing its results of operations for its fiscal quarter ended July 4, 2026. A copy of the press release is attached as Exhibit 99 to this report.

## Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

[99](#) [Press Release of Silicon Laboratories Inc. dated August 11, 2026](#)

104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

### Use of Non-GAAP Financial Information

From time to time, Silicon Laboratories provides certain non-GAAP financial measures as additional information relating to its operating results. The non-GAAP financial measurements provided in the press release furnished herewith do not replace the presentation of Silicon Laboratories’ GAAP financial results. These additional measurements merely provide supplemental information to assist investors in analyzing Silicon Laboratories’ financial position and results of operations; however, these measures are not in accordance with, or an alternative to, GAAP and may be different from non-GAAP measures used by other companies.

Non-GAAP financial measures used by Silicon Laboratories include non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense and non-GAAP research and development expense as a percentage of revenue, non-GAAP selling, general and administrative expense and non-GAAP selling, general and administrative as a percentage of revenue, non-GAAP operating expenses and non-GAAP operating expenses as a percentage of revenue, non-GAAP operating income (loss) and non-GAAP operating income (loss) as a percentage of revenue, non-GAAP income (loss) before income taxes and equity-method earnings (loss), non-GAAP tax expense, non-GAAP tax rate, non-GAAP net income (loss), and non-GAAP diluted earnings (loss) per share. Silicon Laboratories has chosen to provide this information to investors because it believes that such supplemental information enables them to perform meaningful comparisons of past, present and future operating results, and as a means to highlight the results of core ongoing operations.

Non-GAAP financial measures are adjusted by the following items, as applicable for the relevant period:

- *Stock compensation expense* – represents charges for employee stock awards issued under Silicon Laboratories’ stock-based compensation plans. Stock compensation expense is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
  - *Intangible asset amortization* – primarily represents charges for the amortization of intangibles assets, such as core and developed technology, customer relationships and trademarks acquired in connection with business combinations. Intangible asset amortization is excluded from non-GAAP financial measures because it is a non-cash expense, and excluding such expense provides meaningful supplemental information regarding core ongoing operations.
  - *Merger-related costs* – primarily including the following: costs associated with the planned merger with Texas Instruments Incorporated, such as financial advisory, legal, accounting, and other related costs. Merger-related costs are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
  - *Termination costs, impairments, and fair value and other adjustments* – primarily include costs associated with certain employee terminations, asset impairments, fair value adjustments resulting from observable price changes and other non-cash adjustments. Termination costs, impairments, and fair value and other adjustments are excluded from non-GAAP financial measures because excluding such amounts provides meaningful supplemental information regarding core ongoing operations.
  - *Income tax adjustments* – effective from the first quarter of 2026, represents the application of a long-term non-GAAP tax rate of 18% to non-GAAP income before income taxes. The non-GAAP tax rate is determined based on a multi-year forecast that takes into consideration the following: the current and
-

deferred income tax effects of the above non-GAAP adjustments; other indirect impacts of excluding stock-based compensation; and the income tax impact of certain intercompany license arrangements for technology acquired in business combinations. This non-GAAP tax rate also considers factors such as tax structure, tax positions in various jurisdictions, and key legislation in significant jurisdictions where Silicon Laboratories operates. This non-GAAP tax rate may be subject to change for a variety of reasons, including the rapidly evolving global tax environment, significant changes in geographic earnings mix, changes to strategy or business operations, or corporate organizational changes related to acquisitions or tax planning opportunities.

Pursuant to the requirements of Regulation G, Silicon Laboratories has provided in the press release furnished with this report a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. The information contained therein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Silicon Laboratories, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILICON LABORATORIES INC.

August 11, 2026

Date

/s/ Dean Butler

Dean Butler

*Senior Vice President and  
Chief Financial Officer  
(Principal Financial Officer)*



## Silicon Labs Reports Second Quarter 2026 Results

*Wireless IoT leader delivers \$228 million in revenue and strong earnings growth*

**AUSTIN, Texas – August 11, 2026 – Silicon Labs** (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the second quarter, which ended July 4, 2026.

“We delivered revenue of \$228 million, continuing our strong sequential and year-over-year growth - a testament to the execution and dedication of the Silicon Labs team,” said Matt Johnson, President and Chief Executive Officer. “Overall profitability improved meaningfully in the quarter, demonstrating the operating leverage inherent in our model. Gross margin was nearly 62%, reflecting the value customers place on our industry-leading solutions.”

### Second Quarter Financial Highlights

- Revenue was \$228 million, up 18% year-over-year
- Industrial & Commercial revenue was \$135 million, up 23% year-over-year
- Home & Life revenue was \$93 million, up 12% year-over-year
- Bookings and new orders accelerated, while inventory at both our distributors and end customers declined
- Medical achieved record revenue in the quarter, up 78% year-over-year
- Total opportunity funnel and design wins both materially accelerated, reinforcing our durable growth trajectory
- GAAP diluted loss per share was \$(0.32), improving by 52% over the comparable period last year
- Non-GAAP diluted earnings per share was \$0.71, up 545% over the comparable period last year

Results on a GAAP basis:

- GAAP gross margin was 61.6%
- GAAP operating expenses were \$151 million
- GAAP operating loss was \$11 million
- GAAP diluted loss per share was \$(0.32)

Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:

- Non-GAAP gross margin was 61.9%
- Non-GAAP operating expenses were \$114 million
- Non-GAAP operating income was \$27 million
- Non-GAAP diluted earnings per share was \$0.71

Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.

### About Silicon Labs

Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at [silabs.com](https://silabs.com).

## Forward-Looking Statements

This press release contains forward-looking statements regarding Silicon Labs' current expectations, which are based on its current views and assumptions. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward looking. These forward-looking statements include, but are not limited to, Silicon Labs' expectations regarding its near- and long-term strength and durable growth trajectory and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of public health crises on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks; risks associated with any material weakness in our internal controls over financial reporting; risks relating to compliance with laws and regulations; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.

*Note to editors: Silicon Laboratories, Silicon Labs, the "S" symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.*

For more information: Silicon Labs Investor Relations, [investor.relations@silabs.com](mailto:investor.relations@silabs.com)

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Operations**  
(In thousands, except per share data)  
(Unaudited)

|                                             | Three Months Ended |                    | Six Months Ended   |                    |
|---------------------------------------------|--------------------|--------------------|--------------------|--------------------|
|                                             | July 4,<br>2026    | July 5,<br>2025    | July 4,<br>2026    | July 5,<br>2025    |
| Revenues                                    | \$ 228,189         | \$ 192,845         | \$ 441,689         | \$ 370,559         |
| Cost of revenues                            | 87,515             | 84,736             | 174,017            | 164,673            |
| Gross profit                                | 140,674            | 108,109            | 267,672            | 205,886            |
| Operating expenses:                         |                    |                    |                    |                    |
| Research and development                    | 95,016             | 87,821             | 183,610            | 176,040            |
| Selling, general and administrative         | 56,324             | 43,155             | 111,810            | 84,793             |
| Operating expenses                          | 151,340            | 130,976            | 295,420            | 260,833            |
| Operating loss                              | (10,666)           | (22,867)           | (27,748)           | (54,947)           |
| Other income (expense):                     |                    |                    |                    |                    |
| Interest income and other, net              | 2,489              | 3,833              | 6,115              | 7,626              |
| Interest expense                            | (251)              | (251)              | (483)              | (535)              |
| Loss before income taxes                    | (8,428)            | (19,285)           | (22,116)           | (47,856)           |
| Provision for income taxes                  | 2,164              | 2,532              | 4,373              | 4,431              |
| Net loss                                    | <u>\$ (10,592)</u> | <u>\$ (21,817)</u> | <u>\$ (26,489)</u> | <u>\$ (52,287)</u> |
| Loss per share:                             |                    |                    |                    |                    |
| Basic                                       | \$ (0.32)          | \$ (0.67)          | \$ (0.80)          | \$ (1.61)          |
| Diluted                                     | \$ (0.32)          | \$ (0.67)          | \$ (0.80)          | \$ (1.61)          |
| Weighted-average common shares outstanding: |                    |                    |                    |                    |
| Basic                                       | 33,206             | 32,682             | 33,084             | 32,570             |
| Diluted                                     | 33,206             | 32,682             | 33,084             | 32,570             |

## Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

### Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

| Non-GAAP Income Statement Items     | Three Months Ended<br>July 4, 2026 |                         |                            |                               |                      |                  |                             |
|-------------------------------------|------------------------------------|-------------------------|----------------------------|-------------------------------|----------------------|------------------|-----------------------------|
|                                     | GAAP Measure                       | GAAP Percent of Revenue | Stock Compensation Expense | Intangible Asset Amortization | Merger-Related Costs | Non-GAAP Measure | Non-GAAP Percent of Revenue |
| Revenues                            | \$ 228,189                         |                         |                            |                               |                      |                  |                             |
| Gross profit                        | 140,674                            | 61.6%                   | \$ 463                     | \$ —                          | \$ —                 | \$ 141,137       | 61.9%                       |
| Research and development            | 95,016                             | 41.6%                   | 12,902                     | 2,295                         | 3,289                | 76,530           | 33.5%                       |
| Selling, general and administrative | 56,324                             | 24.7%                   | 12,284                     | —                             | 6,258                | 37,782           | 16.6%                       |
| Operating expenses                  | 151,340                            | 66.3%                   | 25,186                     | 2,295                         | 9,547                | 114,312          | 50.1%                       |
| Operating income (loss)             | (10,666)                           | (4.7%)                  | 25,649                     | 2,295                         | 9,547                | 26,825           | 11.8%                       |

| Non-GAAP Earnings (Loss) Per Share | Three Months Ended<br>July 4, 2026 |                                 |                                |                       |                          |    | Non-GAAP Measure |
|------------------------------------|------------------------------------|---------------------------------|--------------------------------|-----------------------|--------------------------|----|------------------|
|                                    | GAAP Measure                       | Stock Compensation Expense*     | Intangible Asset Amortization* | Merger-Related Costs* | Income Tax Adjustments** |    |                  |
| Net income (loss)                  | \$ (10,592)                        | \$ 25,649                       | \$ 2,295                       | \$ 9,547              | \$ (3,067)               | \$ | 23,832           |
|                                    |                                    | Shares Excluded Due to Net Loss |                                |                       |                          |    |                  |
| Diluted shares outstanding         | 33,206                             |                                 | 504                            |                       |                          |    | 33,710           |
| Diluted earnings (loss) per share  | \$ (0.32)                          |                                 |                                |                       |                          | \$ | 0.71             |

\* Represents pre-tax amounts

\*\* Represents the application of an 18% non-GAAP tax rate

**Silicon Laboratories Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except per share data)  
(Unaudited)

|                                                                                                                                                                 | July 4,<br>2026     | January 3,<br>2026  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|
| <b>Assets</b>                                                                                                                                                   |                     |                     |
| Current assets:                                                                                                                                                 |                     |                     |
| Cash and cash equivalents                                                                                                                                       | \$ 362,191          | \$ 364,222          |
| Short-term investments                                                                                                                                          | 35,051              | 79,400              |
| Accounts receivable, net                                                                                                                                        | 79,801              | 64,513              |
| Inventories                                                                                                                                                     | 123,340             | 95,566              |
| Prepaid expenses and other current assets                                                                                                                       | 70,840              | 70,316              |
| Total current assets                                                                                                                                            | 671,223             | 674,017             |
| Property and equipment, net                                                                                                                                     | 130,902             | 128,643             |
| Goodwill                                                                                                                                                        | 376,389             | 376,389             |
| Other intangible assets, net                                                                                                                                    | 18,541              | 23,130              |
| Other assets, net                                                                                                                                               | 56,001              | 67,138              |
| Total assets                                                                                                                                                    | <u>\$ 1,253,056</u> | <u>\$ 1,269,317</u> |
| <b>Liabilities and Stockholders' Equity</b>                                                                                                                     |                     |                     |
| Current liabilities:                                                                                                                                            |                     |                     |
| Accounts payable                                                                                                                                                | \$ 52,407           | \$ 50,717           |
| Deferred revenue and returns liability                                                                                                                          | 5,176               | 5,359               |
| Other current liabilities                                                                                                                                       | 66,563              | 87,711              |
| Total current liabilities                                                                                                                                       | 124,146             | 143,787             |
| Other non-current liabilities                                                                                                                                   | 34,108              | 31,112              |
| Total liabilities                                                                                                                                               | 158,254             | 174,899             |
| Commitments and contingencies                                                                                                                                   |                     |                     |
| Stockholders' equity:                                                                                                                                           |                     |                     |
| Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued                                                                                | —                   | —                   |
| Common stock – \$0.0001 par value; 250,000 shares authorized; 33,366 and 32,955 shares issued and outstanding at July 4, 2026 and January 3, 2026, respectively | 3                   | 3                   |
| Additional paid-in capital                                                                                                                                      | 184,456             | 157,402             |
| Retained earnings                                                                                                                                               | 910,325             | 936,814             |
| Accumulated other comprehensive income                                                                                                                          | 18                  | 199                 |
| Total stockholders' equity                                                                                                                                      | 1,094,802           | 1,094,418           |
| Total liabilities and stockholders' equity                                                                                                                      | <u>\$ 1,253,056</u> | <u>\$ 1,269,317</u> |

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

|                                                                                           | Six Months Ended  |                   |
|-------------------------------------------------------------------------------------------|-------------------|-------------------|
|                                                                                           | July 4,<br>2026   | July 5,<br>2025   |
| <b>Operating Activities</b>                                                               |                   |                   |
| Net loss                                                                                  | \$ (26,489)       | \$ (52,287)       |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |                   |                   |
| Depreciation of property and equipment                                                    | 12,171            | 12,701            |
| Amortization of other intangible assets                                                   | 4,589             | 8,780             |
| Stock-based compensation expense                                                          | 46,704            | 39,605            |
| Deferred income taxes                                                                     | 1,663             | 1,504             |
| Changes in operating assets and liabilities:                                              |                   |                   |
| Accounts receivable                                                                       | (15,289)          | (2,017)           |
| Inventories                                                                               | (27,734)          | 24,631            |
| Prepaid expenses and other assets                                                         | (803)             | 5,112             |
| Accounts payable                                                                          | 2,051             | 12,812            |
| Other current liabilities and income taxes                                                | (7,925)           | 8,377             |
| Deferred revenue and returns liability                                                    | (183)             | 783               |
| Other non-current liabilities                                                             | 1,667             | (6,965)           |
| Net cash provided by (used in) operating activities                                       | (9,578)           | 53,036            |
| <b>Investing Activities</b>                                                               |                   |                   |
| Purchases of marketable securities                                                        | —                 | (32,507)          |
| Sales of marketable securities                                                            | —                 | 14,986            |
| Maturities of marketable securities                                                       | 44,119            | 17,019            |
| Purchases of property and equipment                                                       | (22,153)          | (13,549)          |
| Proceeds from capital-related government incentives                                       | 5,272             | —                 |
| Net cash provided by (used in) investing activities                                       | 27,238            | (14,051)          |
| <b>Financing Activities</b>                                                               |                   |                   |
| Payment of taxes withheld for vested stock awards                                         | (27,451)          | (13,752)          |
| Proceeds from the issuance of common stock                                                | 7,760             | 7,619             |
| Net cash used in financing activities                                                     | (19,691)          | (6,133)           |
| Increase (decrease) in cash and cash equivalents                                          | (2,031)           | 32,852            |
| Cash and cash equivalents at beginning of period                                          | 364,222           | 281,607           |
| Cash and cash equivalents at end of period                                                | <u>\$ 362,191</u> | <u>\$ 314,459</u> |